TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07666490: A Pragmatic, Phase IV, Randomized, Open-label, Multinational, Multicentre, 2-arm Parallel Group, Prospective Study Comparing Efficacy and Safety of Single Inhaler ICS/LABA/LAMA (Beclometasone/Formoterol Fumarate/Glycopyr

Sponsor: Chiesi Farmaceutici S.p.A. · Phase: PHASE4 · Area: IMMUNOLOGY · Target Enrollment: 644 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,832,000

Rescue Site Savings

+$5,823,600

Unlock Full NCT07666490 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07666490 Rescue Dossier →